A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer

A Naeim, PR Ward, HJ Wang, R Dichmann… - Journal Of Geriatric …, 2013 - Elsevier
Objectives This study aims to determine the efficacy and tolerability of capecitabine (CAP)
plus bevacizumab (BEV) as treatment for frontline metastatic colorectal cancer (mCRC) in …
被引用次数：15 相关文章

A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer

A Naeim, PR Ward, HJ Wang… - Journal of Geriatric …, 2013 - geriatriconcology.net
Objectives This study aims to determine the efficacy and tolerability of capecitabine (CAP)
plus bevacizumab (BEV) as treatment for frontline metastatic colorectal cancer (mCRC) in …

A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer

A Naeim, PR Ward, HJ Wang, R Dichmann… - Journal of Geriatric …, 2013 - infona.pl
This study aims to determine the efficacy and tolerability of capecitabine (CAP) plus
bevacizumab (BEV) as treatment for frontline metastatic colorectal cancer (mCRC) in frail …

A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer.

A Naeim, PR Ward, HJ Wang, R Dichmann… - Journal of Geriatric …, 2013 - europepmc.org
Objectives This study aims to determine the efficacy and tolerability of capecitabine (CAP)
plus bevacizumab (BEV) as treatment for frontline metastatic colorectal cancer (mCRC) in …

A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer

A Naeim, PR Ward, HJ Wang… - Journal of geriatric …, 2013 - pubmed.ncbi.nlm.nih.gov
Objectives This study aims to determine the efficacy and tolerability of capecitabine (CAP)
plus bevacizumab (BEV) as treatment for frontline metastatic colorectal cancer (mCRC) in …